Kezar Life Sciences Inc (NASDAQ:KZR) has earned an average recommendation of “Buy” from the seven brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $12.00.
Several research analysts have commented on KZR shares. HC Wainwright reissued a “buy” rating and set a $12.00 price objective (up previously from $9.00) on shares of Kezar Life Sciences in a report on Thursday, June 4th. ValuEngine lowered shares of Kezar Life Sciences from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 4th. Cowen reaffirmed an “outperform” rating on shares of Kezar Life Sciences in a research report on Sunday, June 14th. BidaskClub lowered shares of Kezar Life Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, June 5th. Finally, William Blair reaffirmed a “buy” rating on shares of Kezar Life Sciences in a research report on Friday, March 13th.
In other Kezar Life Sciences news, major shareholder Equal Talent Investments Ltd bought 1,454,545 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average cost of $5.50 per share, for a total transaction of $7,999,997.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Franklin M. Berger bought 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $4.84 per share, with a total value of $484,000.00. Following the completion of the transaction, the director now directly owns 784,003 shares of the company’s stock, valued at $3,794,574.52. The disclosure for this purchase can be found here. Insiders own 7.60% of the company’s stock.
KZR stock traded down $0.24 during trading on Monday, reaching $5.41. The company’s stock had a trading volume of 1,365,600 shares, compared to its average volume of 562,910. Kezar Life Sciences has a 1 year low of $2.18 and a 1 year high of $9.79. The company has a quick ratio of 18.69, a current ratio of 18.69 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $206.55 million, a P/E ratio of -3.11 and a beta of 0.11. The company’s fifty day moving average is $5.53 and its 200-day moving average is $4.37.
Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.37) by $0.07. Analysts anticipate that Kezar Life Sciences will post -1.13 earnings per share for the current year.
Kezar Life Sciences Company Profile
Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.
Read More: What is Depreciation?
Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.